Indivior to Acquire Opiant Pharmaceuticals for ~$145M
Shots:
- Indivior to acquire all outstanding shares of Opiant for up front of $20.00/share (~$145M) representing a premium of 111% to the closing share price of Nov 11, 2022
- Opiant shareholders will also receive ~$8.00/share in CVRs incl. $2/CVR in 3 tranches if OPNT-003 achieves net revenues of $225M, $300M &. $325M for four quarters prior to the 7th yr. & $2/CVR if OPNT-003 achieves net revenues of $225M prior to the 3rd yr. in the US. The transaction is expected to be close in Q1’23
- The acquisition will accelerate Indivior’s portfolio of therapies & launch of OPNT003 by using its expertise and resources for opioid overdose. The NDA submission of OPNT003 to the US FDA is expected to be completed in Q4’22 & the product is expected to launch in the US in the coming months
Ref: Businesswire | Image: Opiant Pharmaceuticals
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
